Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales

Kyntra Bio reported mixed second-quarter results on an earnings call. Revenue turned negative to $1.5 million, down from $1.3 million a year earlier, while net income improved to $12 million, or $2.96 per share, compared with a loss of $13.7 million, or $3.38 per share. Operating expenses increased 20% to $16.1 million, with research and development spending up 15.3% to $6.8 million and selling, general and administrative expenses rising 31% to $9.3 million.

The company has $95.7 million in cash, investments and receivables, with a cash runway extending into 2028. Key clinical programs include FG-3246, a CD46-targeted prostate cancer therapy on track for Phase II interim analysis in Q4 2026, and roxadustat, an oral treatment for lower-risk myelodysplastic syndromes moving toward a Phase III start in Q4 2026.

Management emphasized the company's strong balance sheet and pipeline progress despite the weak operating results, stating that the profit was likely driven by non-operating items rather than core business strength.